Latest News
AveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
Today, AveXis, Inc. presented an interim analysis of data as of April 1, 2016 from the ongoing Phase 1 trial of AVXS-101 for the treatment of spinal muscular atrophy (SMA) […]
Read More ›Cure SMA Announces 2016 Family Friendly Poster Session Presenters
The Family Friendly Research Poster Session is one of the most anticipated events of our Annual SMA Conference. Each year, Cure SMA invites researchers from the SMA Researcher Meeting, which […]
Read More ›Cure SMA Welcomes New Board and Committee Members
Recently, Cure SMA confirmed three new board members and several new committee members. These new members will provide additional leadership in the areas of advocacy, FDA/regulation, and research. We extend […]
Read More ›Ionis Releases Data Update from Phase 2 Study in Infants with SMA
Ionis Pharmaceuticals provided an update on its ongoing open-label Phase 2 clinical study of nusinersen in infants with spinal muscular atrophy (SMA) at the American Academy of Neurology (AAN) meeting. […]
Read More ›Cure SMA and the SMA Community Featured by Astellas Pharmaceuticals
Cure SMA is featured by Astellas Pharmaceuticals as part of their new Changing Tomorrow Together website. Cure SMA Research Director Jill Jarecki contributed a spotlight piece about Cure SMA’s research […]
Read More ›Annual SMA Conference to Host Panels on NDA Process and SMA Drugs in Development
One of the most significant aspects of the Annual SMA Conference is the bringing together of families and researchers in the same event. The 2016 Annual SMA Conference is poised […]
Read More ›